Generic Medicine Info
May be taken with or without food.
Severe respiratory insufficiency, sleep apnoea, myasthenia gravis. As single agent for the treatment of insomnia associated with depression. Severe hepatic impairment. Pregnancy and lactation.
Special Precautions
Patient with depression, mild to moderate chronic respiratory insufficiency, CV or cerebrovascular disease, personality disorders, narrow angle glaucoma, history of alcohol or drug abuse. Not indicated for the primary treatment of depressive disorders or psychotic illness. Avoid abrupt withdrawal. Mild to moderate hepatic impairment and renal impairment. Elderly, debilitated, and patients at risk of falls. Concomitant use with opioids. Patient Counselling This drug may cause sedation, amnesia, dizziness, and impaired cognitive or muscular function, if affected, do not drive or operate machinery. Monitoring Parameters Monitor CBC, LFT, renal function, and respiratory status.
Adverse Reactions
Significant: Blood dyscrasias, respiratory depression, CNS depression, anterograde amnesia, sleep related activities (e.g. sleep-driving), paradoxical reactions (e.g. restlessness, agitation, irritability, aggressive behaviour, rage, delusion, hallucinations, nightmares, psychoses), encephalopathy, elevated liver enzymes, suicidal ideation, physical and psychological dependence. Rarely, hypotension. General disorders and administration site conditions: Asthenia, fatigue. Musculoskeletal and connective tissue disorders: Muscle weakness. Nervous system disorders: Daytime drowsiness, sedation, dizziness, ataxia.
Drug Interactions
Increased risk of profound sedation, respiratory depression, coma, and death with opioids. Enhanced CNS depressant effect with barbiturates, antipsychotics, antidepressants, antihistamines, anticonvulsants, anaesthetics, other sedative/hypnotics, and anxiolytics. Increased activity with CYP450 inhibitors. Decreased sedative activity with theophylline or aminophylline. Increased hypotensive effect with antihypertensive agents.
CIMS Class
Hypnotics & Sedatives
ATC Classification
N05CD06 - lormetazepam ; Belongs to the class of benzodiazepine derivatives. Used as hypnotics and sedatives.
Disclaimer: This information is independently developed by CIMS based on lormetazepam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in